August 2018 FDA Recall Drug by Pfizer Inc.
D-1184-2018 - Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point
This Class III drug recall was voluntarily initiated by Pfizer Inc. on August 28, 2018 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications; out of specification stability testing results at the 18 month time point. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1184-2018
Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point
08-28-2018
09-19-2018
1,580 vials
Recall Profile & Regulatory Data
Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Pfizer Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide USA
06-26-2020
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx only, Sterile, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 USA. NDC: 0409-1140-01
Batch or Lot Expiration Information
Lot# Lot: DP602, 10/2018